JP2024545186A5 - - Google Patents
Info
- Publication number
- JP2024545186A5 JP2024545186A5 JP2024534656A JP2024534656A JP2024545186A5 JP 2024545186 A5 JP2024545186 A5 JP 2024545186A5 JP 2024534656 A JP2024534656 A JP 2024534656A JP 2024534656 A JP2024534656 A JP 2024534656A JP 2024545186 A5 JP2024545186 A5 JP 2024545186A5
- Authority
- JP
- Japan
- Prior art keywords
- raav
- nucleic acid
- sequence
- promoter
- particles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163288519P | 2021-12-10 | 2021-12-10 | |
| US63/288,519 | 2021-12-10 | ||
| PCT/US2022/081321 WO2023108157A1 (en) | 2021-12-10 | 2022-12-09 | Methods and compositions for treating mybpc3 related hypertrophic cardiomyopathy with a viral vector |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024545186A JP2024545186A (ja) | 2024-12-05 |
| JP2024545186A5 true JP2024545186A5 (enExample) | 2025-12-17 |
Family
ID=86731341
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024534656A Pending JP2024545186A (ja) | 2021-12-10 | 2022-12-09 | ウイルスベクターによるｍｙｂｐｃ３関連肥大型心筋症を処置するための方法および組成物 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250041452A1 (enExample) |
| EP (1) | EP4444363A4 (enExample) |
| JP (1) | JP2024545186A (enExample) |
| KR (1) | KR20240122827A (enExample) |
| AU (1) | AU2022408189A1 (enExample) |
| CA (1) | CA3242262A1 (enExample) |
| IL (1) | IL313426A (enExample) |
| WO (1) | WO2023108157A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025051970A2 (en) * | 2023-09-06 | 2025-03-13 | Dinaqor Ag | Methods of treatment of hypertrophic cardiomyopathy with aav gene therapy vectors and therapeutic formulations |
| CN117959432A (zh) * | 2023-12-13 | 2024-05-03 | 上海市第十人民医院 | 一种myl4基因在治疗或预防心房疾病中的应用 |
| WO2025162449A1 (en) * | 2024-01-30 | 2025-08-07 | Inspirar Limited | Compositions and methods for the treatment of heart disease |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2306448A1 (en) * | 1997-10-16 | 1999-04-22 | Board Of Regents, The University Of Texas System | Models and treatments for cardiac hypertrophy in relation with nf-at3 function |
| WO2010037593A1 (en) * | 2008-10-01 | 2010-04-08 | Tet Systems Holding Gmbh & Co.Kg | Tetracycline inducible transcription control sequence |
| WO2017191274A2 (en) * | 2016-05-04 | 2017-11-09 | Curevac Ag | Rna encoding a therapeutic protein |
| DK3684423T5 (da) * | 2017-09-20 | 2024-08-26 | 4D Molecular Therapeutics Inc | Adeno-associerede virusvariantcapsider og fremgangsmåder til anvendelse deraf |
| CN109776680B (zh) * | 2019-01-25 | 2020-05-12 | 浙江蓝盾药业有限公司 | 抗人pcsk9单克隆抗体及其用途 |
| JP7785352B2 (ja) * | 2019-08-14 | 2025-12-15 | ユニバーシティー オブ フロリダ リサーチ ファンデーション， インク． | 遺伝子治療のためのａａｖカプシドバリアント |
| WO2021154923A2 (en) * | 2020-01-29 | 2021-08-05 | Voyager Therapeutics, Inc. | Methods and systems for producing aav particles |
| FI4103214T3 (fi) * | 2020-02-13 | 2026-07-03 | Tenaya Therapeutics Inc | Geeniterapian vektorit sydänsairauden hoitoon |
-
2022
- 2022-12-09 KR KR1020247023075A patent/KR20240122827A/ko active Pending
- 2022-12-09 EP EP22905437.4A patent/EP4444363A4/en active Pending
- 2022-12-09 US US18/717,502 patent/US20250041452A1/en active Pending
- 2022-12-09 CA CA3242262A patent/CA3242262A1/en active Pending
- 2022-12-09 AU AU2022408189A patent/AU2022408189A1/en active Pending
- 2022-12-09 WO PCT/US2022/081321 patent/WO2023108157A1/en not_active Ceased
- 2022-12-09 IL IL313426A patent/IL313426A/en unknown
- 2022-12-09 JP JP2024534656A patent/JP2024545186A/ja active Pending